These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12967952)

  • 1. Pharmacological comparison of the alternatively spliced short and long CCK2 receptors.
    Morton MF; Harper EA; Tavares IA; Shankley NP
    Br J Pharmacol; 2003 Sep; 140(1):218-24. PubMed ID: 12967952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thermodynamic analysis does not allow discrimination of agonists and antagonists at human CCK2S-receptors.
    Harper EA; Mitchell EA; Griffin EP; Kalindjian SB
    Eur J Pharmacol; 2008 Feb; 581(1-2):1-12. PubMed ID: 18158148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological analysis of CCK2 receptors up-regulated using engineered transcription factors.
    Morton MF; Liu PQ; Reik A; de la Rosa R; Mendel M; Li XY; Case C; Pabo C; Moreno V; Pyati J; Shankley NP
    Regul Pept; 2005 Jul; 129(1-3):227-32. PubMed ID: 15927720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCK1 and 2 receptors are expressed in immortalized rat brain neuroblasts: intracellular signals after cholecystokinin stimulation.
    Langmesser S; Cerezo-Guisado MI; Lorenzo MJ; Garcia-Marin LJ; Bragado MJ
    J Cell Biochem; 2007 Mar; 100(4):851-64. PubMed ID: 17226751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCK2 receptors mediate inhibitory effects of cholecystokinin on the motor activity of guinea-pig distal colon.
    Fornai M; Colucci R; Antonioli L; Baschiera F; Ghisu N; Tuccori M; Gori G; Blandizzi C; Del Tacca M
    Eur J Pharmacol; 2007 Feb; 557(2-3):212-20. PubMed ID: 17208221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achiral, selective CCK2 receptor antagonists based on a 1,3,5-benzotriazepine-2,4-dione template.
    Spencer J; Gaffen J; Griffin E; Harper EA; Linney ID; McDonald IM; Roberts SP; Shaxted ME; Adatia T; Bashall A
    Bioorg Med Chem; 2008 Mar; 16(6):2974-83. PubMed ID: 18289857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scaffold hopping with molecular field points: identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists.
    Low CM; Buck IM; Cooke T; Cushnir JR; Kalindjian SB; Kotecha A; Pether MJ; Shankley NP; Vinter JG; Wright L
    J Med Chem; 2005 Nov; 48(22):6790-802. PubMed ID: 16250638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lipopolysaccharide on expression and characterization of cholecystokinin receptors in rat pulmonary interstitial macrophages.
    Xu SJ; Gao WJ; Cong B; Yao YX; Gu ZY
    Acta Pharmacol Sin; 2004 Oct; 25(10):1347-53. PubMed ID: 15456538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different pathways mediated by CCK1 and CCK2 receptors: effect of intraperitonal mrna antisense oligodeoxynucleotides to cholecystokinin on anxiety-like and learning behaviors in rats.
    Cohen H; Kaplan Z; Matar MA; Buriakovsky I; Bourin M; Kotler M
    Depress Anxiety; 2004; 20(3):139-52. PubMed ID: 15487014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.
    McDonald IM; Black JW; Buck IM; Dunstone DJ; Griffin EP; Harper EA; Hull RA; Kalindjian SB; Lilley EJ; Linney ID; Pether MJ; Roberts SP; Shaxted ME; Spencer J; Steel KI; Sykes DA; Walker MK; Watt GF; Wright L; Wright PT; Xun W
    J Med Chem; 2007 Jun; 50(13):3101-12. PubMed ID: 17536796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.
    Morton MF; Barrett TD; Yan W; Freedman JM; Lagaud G; Prendergast CE; Moreno V; Pyati J; Figueroa K; Li L; Wu X; Rizzolio M; Breitenbucher JG; McClure K; Shankley NP
    J Pharmacol Exp Ther; 2007 Nov; 323(2):562-9. PubMed ID: 17684117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin.
    Foucaud M; Archer-Lahlou E; Marco E; Tikhonova IG; Maigret B; Escrieut C; Langer I; Fourmy D
    Regul Pept; 2008 Jan; 145(1-3):17-23. PubMed ID: 17961734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thermodynamic analysis of ligands at cholecystokinin CCK2 receptors in rat cerebral cortex.
    Harper EA; Roberts SP; Kalindjian SB
    Br J Pharmacol; 2007 Aug; 151(8):1352-67. PubMed ID: 17592503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectivity toward CCK2 receptors.
    Muñoz-Ruiz P; García-López MT; Cenarruzabeitia E; Del Río J; Dufresne M; Foucaud M; Fourmy D; Herranz R
    J Med Chem; 2004 Oct; 47(21):5318-29. PubMed ID: 15456276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
    Dong M; Liu G; Pinon DI; Miller LJ
    Biochemistry; 2005 May; 44(17):6693-700. PubMed ID: 15850403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin.
    González-Puga C; García-Navarro A; Escames G; León J; López-Cantarero M; Ros E; Acuña-Castroviejo D
    J Pineal Res; 2005 Oct; 39(3):243-50. PubMed ID: 16150104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists I: discovery of CCKR1 selectivity in a previously CCKR2-selective lead series.
    Pippel M; Allison BD; Phuong VK; Li L; Morton MF; Prendergast C; Wu X; Shankley NP; Rabinowitz MH
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6373-5. PubMed ID: 19811913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of luminal gastrin in the regulation of pancreatic juice secretion in preruminant calves.
    Zabielski R; Normand V; Romé V; Woliński J; Chayvialle JA; Guilloteau P
    Regul Pept; 2004 Jul; 119(3):169-76. PubMed ID: 15120477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrin suppresses growth of CCK2 receptor expressing colon cancer cells by inducing apoptosis in vitro and in vivo.
    Müerköster S; Isberner A; Arlt A; Witt M; Reimann B; Blaszczuk E; Werbing V; Fölsch UR; Schmitz F; Schäfer H
    Gastroenterology; 2005 Sep; 129(3):952-68. PubMed ID: 16143134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1.
    Kohara A; Toya T; Tamura S; Watabiki T; Nagakura Y; Shitaka Y; Hayashibe S; Kawabata S; Okada M
    J Pharmacol Exp Ther; 2005 Oct; 315(1):163-9. PubMed ID: 15976016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.